Nature Reviews Drug Discovery

Article	Citations
New target for anorexia	1736
Alzheimer antibody rush begins, as efficacy concerns remain	1667
Will psychedelics be ‘a revolution in psychiatry’?	1051
Generating neurons in the adult brain	1039
First clinical test of an in vivo CRISPR candidate shows deep protein knockout potential	909
Upcoming market catalysts in Q3 2021	901
New CAR’s bells and whistles	725
Brain glucose mediates amphotericin B tolerance	687
Acyl-lysine reader inhibitor blocks AML progression	654
Identifying selective PI3KC2α inhibitors	608
Putting a PIN in pancreatic cancer	517
A cancer drug wish list	483
FDA approves first-in-class NK3 receptor antagonist for hot flushes	455
Hypoimmune iPSCs escape immune detection	453
Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?	440
A spirulina-based biomanufacturing platform	379
Small-molecule screens for targeting non-coding RNA	377
Vertex’s NaV1.8 inhibitor passes phase II pain point	370
Monoclonal antibody treats yellow fever	363
DENV inhibitor effective in non-human primates	352
Decrypting drug action at the level of PTMs	347
PKN3: a target in cancer metastasis	344
A new path to targeted protein degradation?	339
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	337
Pandemic vaccines: a formidable challenge for pharmacovigilance	336

Neurons give metastatic cells a push	335
Apolipoprotein L2 inhibitor mitigates fibrosis	334
RAS-targeted therapies	314
ASO targets DNA repair protein to combat Huntington disease	313
PKC modulator promotes remyelination	300
FDA approves new non-opioid pain drug	251
Chemical engineering of CRISPR–Cas systems for therapeutic application	247
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	238
Non-antibiotic drug network reveals new leads for antibiotics	233
Kinase inhibitor rescues the liver	229
AI serves up target and inhibitor for lung fibrosis	228
FDA approves first complement factor D inhibitor	225
Synthesizing portimines	224
mRNA flu shots move into trials	221
A ROS-mediated resistance pathway to anticancer drugs	206
The importance of persistence in cancer drug development	202
Novo Nordisk and GlaxoSmithKline buy into RNAi	187
FDA approves first Friedreich’s ataxia drug	184
New naming scheme for antibodies drops the -mab stem	180
Allosteric adenosine receptor modulator alleviates pain	173
Overcoming ICB resistance in lung cancer	173
2024 FDA approvals exceed average number but have lower sales projections	168
Lipid nanoparticle ferries therapeutic mRNA to the placenta	162
Rediscovering hygromycin A for Lyme disease treatment	152
Towards polio eradication	143
Massive misuse of chemical probes undermines the utility of these tools	139
Treating cannabis use disorder	138
What’s next for an immuno-oncology powerhouse?	137
Stalled molecular motor inhibits tumour growth	137
The pipeline and market for migraine drugs	135
Shifts in the clinical trial landscape	135
The KRAS crowd targets its next cancer mutations	132
mRNA-encoded monoclonal antibody fights CHIKV	130
Nanoparticle chirality sets the dial on immunogenicity	130
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	127
FDA new drug approvals in Q1 2023	124
Eli Lilly spends $3.2 billion on Morphic’s oral integrin inhibitor for inflammatory bowel disease	116
Comprehensive measurement of biopharmaceutical R&D investment	114
Epigenetic editor silences prion protein	112
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities	106
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	103
Understanding the effects of antibiotic combinations	103
Ipsen buys Epizyme for US$247 million	100
Promoting tissue repair after heart attack	97
Weeding out toxic RNA in Huntington disease	96
Understanding long-lasting ketamine effects	95
Pasting in large DNA sequences	95
Targeting tumour-associated bacteria	89
FDA new drug approvals in Q1 2021	88
Bacteria tag tumours for CAR-T cell attack	88

First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	86
A specific biomarker for insoluble tau	84
The improving benefit–risk balance of phase I cancer trials	84
Improving circular RNA protein yields	83
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	83
Vaccine exposes tumours to immune cell attack	83
Upcoming market catalysts in Q1 2023	81
Upcoming market catalysts in Q3 2022	81
Neutralizing Zika virus	76
A viral–lipid hybrid delivery system for genetic therapies	75
Pull incentives for antibiotics get push from the UK	73
Novartis’s canakinumab stumbles in cancer, again	72
Open-science drug discovery for COVID-19	69
Gene therapy zeroes in on Parkinson disease brain circuits	68
MYC inhibitor achieves phase I success	67
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	67
A novel approach to boost drug development in paediatric oncology	66
Lipid metabolite triggers neural repair	66
Targeting EMT in cancer through netrin-1	64
A new European platform for advancing regulatory science research	63
Anti-oncostatin M antibody puts brakes on asthma exacerbations	62
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	62
Targeting drug-resistant glioblastoma	62
FDA approves first biparatopic antibody therapy	61
Trust in Science: a novel research partnership model in Latin America	61
FDA approves first all-oral sleeping sickness drug	60
Life science ecosystems in Asia: biomedical innovation trends over the past decade	60
LRRK2 inhibitor progresses for Parkinson disease	59
ASO to treat Timothy syndrome	59
Disease interception at scale: how a five-million-person study plans to transform healthcare	58
Splice-switching ASO curtails brain calcification	56
Top companies and drugs by sales in 2021	56
Degrading cell-free DNA to prevent recurrent stroke	54
Creating an AI-first drug discovery engine	54
Trustworthy AI for safe medicines	53
Author Correction: Disease modification in inflammatory skin disorders: opportunities and challenges	53
Advanced technologies for the development of infectious disease vaccines	52
Protein isoform-centric therapeutics: expanding targets and increasing specificity	52
Antiviral target compound profile for pandemic preparedness	50
Author Correction: B cell depletion therapies in autoimmune disease: advances and mechanistic insights	47
RNA-rewriting candidate moves into the clinic	46
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	46
Suppressing tumour Treg cells with a histone demethylase inhibitor	46
opnMe.com: a digital initiative for sharing tools with the biomedical research community	44
PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx	43
Anti-tau antibody stumbles in phase II Alzheimer trial	38
Glucose-sensitive insulin protects against hypoglycaemia	36
Targeting neurofibrosis reverses metabolic dysfunction	35
Tumour cells get a dendritic cell makeover	34
Targeting tumour N-glycosylation	34
Author Correction: Bridging the gap between innovation and later-stage financing for biotech in Europe	34
Antibody vanquishes SARS-CoV-2 variants	34
Double setback for ASO trials in Huntington disease	32
Comparing development strategies for PD1/PDL1-based immunotherapies	31
FDA approves first hypoxia-inducible factor prolyl hydroxylase inhibitor	31
De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors	30
NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease	29
Muscarinic drugs breathe new life into schizophrenia pipeline	29
Bispecific antibodies in oncology	29
Thinking outside the box: non-canonical targets in multiple sclerosis	28
FDA approves second TTR stabilizer for cardiac amyloidosis	27
Identifying novel antibiotic targets	27
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing	27
Two routes to tamp down microglia in traumatic brain injury	25
Ribosome-targeted antibiotic tackles antimicrobial resistance	25
Insights into new approach methodology innovation: an EMA perspective	25
FDA approves first-in-class AKT inhibitor	25
Impact of regulatory system changes on the availability of innovative drugs in China	25
Evolution of innovative drug R&D in China	24
Delivering on the promise of protein degraders	23
Targeting inflammation in atherosclerosis — from experimental insights to the clinic	23
The landscape and market for HIV therapies	23
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation	22
The glymphatic system: implications for drugs for central nervous system diseases	22
The R&D landscape for infectious disease vaccines	22
The evolving role of investigative toxicology in the pharmaceutical industry	22
Function and therapeutic value of astrocytes in neurological diseases	22
FDA approves second RNA aptamer	22
mRNA vaccines for infectious diseases — advances, challenges and opportunities	22
Trends in kinase drug discovery: targets, indications and inhibitor design	20

Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections	20
FDA approves 100th monoclonal antibody product	19
Amplifying gene expression with RNA-targeted therapeutics	19
Accelerating antiviral drug discovery: lessons from COVID-19	19
Therapeutic targeting of the functionally elusive TAM receptor family	19
Therapeutic RNA-silencing oligonucleotides in metabolic diseases	19
2022 FDA approvals	19
FDA approves first schizophrenia drug with new mechanism of action since 1950s	18
eTRANSAFE: data science to empower translational safety assessment	18
Small-molecule discovery through DNA-encoded libraries	18
Emerging concepts in the science of vaccine adjuvants	18
Therapeutic strategies for COVID-19: progress and lessons learned	17
Targeting HER2-positive breast cancer: advances and future directions	17
Engineering the next generation of cell-based therapeutics	17
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	17
Tripeptide treats NASH in non-human primates	16
Clipping cell-surface mucins in cancer by targeted degradation	16
Upcoming FDA approval decisions in Q2 2025	16
Antibody offers broad alphavirus protection	16
Machine learning identifies AMPs	16
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer	15
DUBTACs for targeted protein stabilization	15
Screening ultra-large virtual libraries	15
A new antibiotic for A. baumannii	14
The landscape of small-molecule prodrugs	14
Upcoming market catalysts in Q3 2023	14
Understanding sphingosine-1-phosphate transport	14
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies	14
A closer look at molecular glues	13
Repurposing sapanisertib in malaria	13
A type 1 regulatory T cell-based therapy	13
FDA releases tissue-agnostic cancer drug draft guidance	13
Identifying degrader hotspots	13
Reflections on 10 years of the FDA’s breakthrough therapy designation	12
Plant protein blocks tumour growth	12
IMI European Lead Factory — democratizing access to high-throughput screening	12
From pandemic preparedness to public–private partnerships	12
Efficiency, effectiveness and productivity in pharmaceutical R&D	12
Upcoming market catalysts in Q4 2021	11
Towards a pan-serotype dengue antiviral	11
Nonhormonal target for endometriosis	11
Preclinical cancer research suffers another reproducibility blow	11
FDA new drug approvals in Q2 2023	11
Understanding PI3K inhibitor mechanism of action	11
Restoring memory in aged mice	11
Phosphatase inhibitor drives anticancer immune responses	10
CRISPR technologies are going to need a bigger toolbox	10
Microbiome screening platform finds drugs for bugs	10
Psychedelic treatment for anorexia	10
Pushing both sides of the drug pricing aisle	10
FDA approves long-acting RSV antibody	10
Molecular glue-like STING activator	10
Alnylam scores big pharma support for angiotensinogen silencer	10
Obesity drug scores landmark cardiovascular win	10
Approvals by the China NMPA in 2024	9
Industrializing engineered autologous T cells as medicines for solid tumours	9
Degrading aurora kinase A in neuroblastoma	9
FDA approves first chikungunya vaccine	9
Designer proteins take the bite out of snake venom	9
An mRNA universal vaccine for influenza	8
Profiling AAV tropism	8
Trends in drug development for amyotrophic lateral sclerosis	8
Targeting cytokine networks in neuroinflammatory diseases	8
A route to small-molecule Lp(a) inhibitors for heart disease	8
Blocking breast cancer metastasis	8
Understanding immunomodulatory antibody agonism	8
Bispecific antibodies pin down cancer stem cells	8
Two competing RSV vaccines round final phase III corner	8
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	8
A call to action for translational sciences in COVID-19 and future pandemics	8
The pipeline and market for psoriasis drugs	8
Host-directed antiviral blocks SARS-CoV-2 entry	8
FDA new drug approvals in Q1 2022	8
Muscarinic receptor modulators for schizophrenia attract multibillion-dollar attention	8
NUAK1 inhibition prevents fibrosis	7
Next-generation gene-editing platforms drive CRISPR deals	7
FDA approves first claudin-18.2-targeted antibody for gastric cancer	7
Loss of Y chromosome promotes cardiac fibrosis	7
FDA new drug approvals in Q2 2021	7
Stress can be exhausting for T cells	7
SLC15A4 inhibitor blocks inflammation	7
Inhibiting ASGR1 boosts cholesterol removal	7
BMP9 stands up to sepsis	7
Antibody cocktail eliminates ebolaviruses	7
Rewired proteostasis in KRAS inhibitor resistance	7
How GLP-1 went from being a hard-to-handle hormone to a blockbuster success	7
Targeting lipid–protein interaction in AML	7
2021 FDA approvals: value driven by COVID-19 vaccines	6
Interfering viral-like particles inhibit SARS-CoV-2 replication	6
Healing wounds without scarring	6
Targeting viruses in their phase	6
Small molecule improves muscle function in myasthenia gravis	6
Trends in the use of liquid biopsy in oncology	6
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	6
Top product forecasts for 2022	6